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Abstract: a new series of bisphosphonates bearing either the nitrogen containing NO-donor furoxan 
(1,2,5-oxadiazole 2-oxide) system or the related furazan (1,2,5-oxadiazole) in lateral chain has been 
developed. pKa values and affinity for hydroxyapatite were determined for all the compounds. The 
products were able to inhibit osteoclastogenesis on RAW 246.7 cells at 10 M concentration. The most 
active compounds were further assayed on human PBMC cells and on rat microsomes. Unlike most 
nitrogen-containing bisphosphonates which target farnesyl pyrophosphate synthase, experimental and 
theoretical investigations suggest that the activity of our derivatives may be related to different 
mechanisms. The furoxan derivatives were also tested for their ability to relax rat aorta strips in view of 
their potential NO-dependent vasodilator properties. 
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Bisphosphonates (BPs) (1, Figure 1) are a class of compounds which contain the P-C-P substructure that, 
unlike the P-O-P moiety present in pyrophosphate (2, Figure 1), is resistant to chemical and enzymatic 
hydrolysis. They are able to accumulate on the bone mineral surface, as a consequence of their capacity of 
chelating calcium ions, and, once there, to inhibit bone resorption following internalisation by bone-
resorbing osteoclasts (OCs). The affinity to the mineral calcium is increased by the presence of a hydroxy 
group on the carbon bearing the two phosphonic functions (1, R’ = OH).1 
The OCs derive from cells of monocyte-macrophage lineage, which fuse to form bone-resorbing cells in 
the presence of Macrophage Colony Stimulating Factor (M-CSF) and Receptor Activator of Nuclear 
factor kB Ligand (RANKL).
2
 A number of BPs are in clinical practice or used in clinical trials for the 
treatment and prevention of excessive osteoclast-mediated bone resorption typical of certain pathologic 
states, including Paget’s disease, and post-menopausal or glucocorticoid-induced osteoporosis.3,4 There is 
also extensive in vitro and in vivo preclinical evidence that some BPs, particularly the most potent 
compounds containing a nitrogen atom in the lateral chain (N-BPs), possess antitumor activity and can 
reduce skeletal tumor burden and inhibit formation of bone metastases in animal models.
5
 BPs can affect 
osteoclasts through two different molecular mechanisms.
3,6
 The former, which is typical of products 
devoid of nitrogen and containing short R and R’ side chains (first generation BPs, Figure 1),6 is their 
incorporation into non-hydrolysable ATP analogues. These metabolites accumulate in the cell cytoplasm 
with consequent inhibition of numerous intracellular metabolic enzymes, resulting in detrimental effects 
on cell function and survival. The latter, which is typical of second and third generation N-BPs (Figure 1, 
N-aliphatic and N-heteroaromatic respectively)
7
 is the blockade of protein prenylation due to their ability 
to inhibit the mevalonate pathway. The main biochemical target of bisphosphonates is farnesyl 
pyrophosphate synthase (FPPS), an enzyme of the presqualenic part of the sterol biosynthetic pathway. 
Some BPs were found to inhibit the conversion of farnesyl pyrophosphate to geranylgeranyl 
pyrophosphate through the blockade of geranylgeranyl pyrophosphate synthase (GGPPS); the consequent 
inhibition of protein geranylgeranylation would then lead to apoptotic programmed cell death.
8
 
Ibandronate and other derivatives also behave as inhibitors of squalene synthase, although their anti-
 4 
resorptive potency does not parallel their degree of inhibition of this enzyme.
9 
Interestingly, BPs have 
been shown to inhibit atherogenesis.
10
 They accumulate extensively in arterial walls where they suppress 
macrophages in atheromatous lesions, inhibit arterial calcification and lipid accumulation. Recently, great 
interest is being taken in BPs, also in view of the emerging relationship between osteoporosis and 
cardiovascular disease (CD).
11,12 
In this paper we report synthesis, physico-chemical characterisation and pharmacological profile of a new 
series of N-BPs bearing the nitrogen-containing furoxan (1,2,5-oxadiazole 2-oxide) system or the related 
furazan (1,2,5-oxadiazole) in the lateral chain. Since it is known that furoxans can produce NO under the 
action of thiol cofactors,
13
 furoxan bisphosphonates herein described represent a new class of NO-donor 
bisphosphonates (NO-BPs). The corresponding furazan derivatives were taken as references since they 
are unable to release NO. NO is involved in the regulation of many physiological processes. In the 
cardiovascular system it plays important roles in maintaining micro and macrovascular homeostasis 
through a number of mechanisms including vascular relaxation, inhibition of platelet aggregation and 
smooth muscle cell proliferation, modulation of monocyte and platelet adhesion.
14,15
 Its impaired 
production is associated to many forms of CD; among them, atrial fibrillation and atherosclerosis. It is 
also an essential modulator of gastric mucosal defence.
16
 Nitric oxide plays a role in bone remodelling, 
affecting osteoclast and osteoblast proliferation in a biphasic manner: high concentrations inhibit 
formation of these bone cells, while low concentrations support their development.
17
 
Therefore, NO-BPs could represent interesting tools in therapy to limit bone loss and atherogenesis. In 
addition, they could display reduced gastric irritation
1
 and atrial fibrillation risk,
18
 two well known 
drawbacks of BPs. 
2. Results and Discussion 
2.1 Chemistry 
The synthetic route to the target compounds is outlined in Schemes 1-3. Phenylfurazan and 
phenylfuroxan BPs 12 and 12a were easily obtained starting from nitrofurazan and nitrofuroxan 
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derivatives 7 and 7a, respectively. These products were reacted with tetraethyl 5-hydroxypentylidene 
bisphosphonate 9 in the presence of t-BuO
-
K
+
 to afford intermediate phosphonates 10, 10a, which were 
transformed into the final acids by action of bromotrimethylsilane (TMSBr) and methanol. Similarly, 
phenylsulfonylfurazan and phenylsulfonylfuroxan BPs 13, 13a were obtained starting from 
bis(phenylsulfonyl) substituted furazan and furoxan 8 and 8a respectively, through intermediates 11, 11a 
(Scheme 1). 
BPs 19, 19a, 20, 20a, bearing a hydroxyl group on the carbon adjacent to phosphonic functions, were 
prepared starting from the phenylsulfonyl substituted furazans 8, 14 and furoxans 8a, 14a by nucleophilic 
displacement of one phenylsulfonyl group under the action of 1,5-pentanediol. This reaction afforded the 
intermediate alcohols 15, 15a, 16, 16a which were subsequently oxidised to the related acids 17, 17a, 18, 
18a using Jones reagent. The reaction of these products with thionyl chloride generated the corresponding 
acylchlorides A, which, without further purification, were treated with trimethyl phosphite in dry THF to 
yield the related acylphosphonates B (Michaelis-Arbuzov reaction). The products were immediately 
transformed into the expected tetramethyl 1-hydroxybisphosphonates C by action of dimethylphosphite in 
dry THF, in the presence of diethylamine. These esters were purified by flash chromatography and 
immediately transformed into the final BPs under the action of TMSBr and methanol (Scheme 2). 
The analogues of alendronate 24, 24a, 25, 25a bearing furazan and furoxan substructures were prepared 
from bromomethylsubstituted furazans and furoxans 21, 21a, 22, 22a by action of N-methylalendronate 
23 (Scheme 3). 
2.2 Dissociation constants 
In Table 1 the pKa values of the final bisphosphonic acids are reported. They were measured by pH-
metric method using a Sirius GLpKa instrument. In the case of BPs not bearing an amino nitrogen in the 
lateral chain, four dissociation constants were detected. This is in keeping with the very low basicity of 
the furazan and furoxan rings that, in the pH range studied (1.2-12), do not undergo protonation.
19
 The 
pKa1 value, corresponding to the first ionization of the bisphosphonic group, is not detectable by this 
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method because it is too low. All the pKa values are in keeping with those found for similar 
compounds.
20,21
 In the case of compounds 24, 24a, 25 and 25a the picture is complicated by the presence 
of a fifth pKa associated with the protonation of the basic nitrogen. These pentaprotic BPs have three 
dissociation constants (pKa1, pKa2, pKa5) corresponding to the first, second, and fourth ionization of the 
bisphosphonic group. In the physiological pH range there are two ionization steps described by pKa3 and 
pKa4 macroconstants that result from overlapping ionizations of the third bisphosphonic group and the 
amino nitrogen in the lateral chain. To assign pKa values to these centres we measured the ionization 
constants in the presence of methanol. The pKa3 and pKa4 were obtained by the plots of the apparent psKa 
values assessed by potentiometric titration in co-solvent mixtures (water/methanol) vs the % methanol (% 
w/w) in the mixtures. Where straight lines with negative slopes were obtained the value was attributed to 
the prevalent ionization of the amine substructure of each compound (pKa4). This behaviour is typical of 
the basic centres.
22 
2.3 Hydroxyapatite affinity 
BPs are trapped by hydroxyapatite (HAP) calcium present at the sites of new bone formation, giving rise 
to the formation of stable complexes. After incorporation in the bone they interact with osteoblasts and 
osteoclasts through a variety of biochemical pathways inducing inhibition of bone resorption. In order to 
evaluate their affinity for HAP, BPs described in the present work were incubated with HAP, according to 
a procedure described elsewhere.
23 
After 0-h, 6-h and 24-h incubation, the residual concentration of BPs 
in solution was determined by reverse phase HPLC. The results obtained are collected in Table 1. As 
expected, ibandronate (5), 1-hydroxy-substituted BPs 19, 19a, 20, 20a and the analogues of alendronate 
24, 24a, 25 and 25a, due to their ability to form tridentate complexes with Ca
2+
, display higher affinity for 
HAP than their analogues 12, 12a, 13, 13a deprived of the hydroxy function. These data are in keeping 
with previous results reported in literature.
6
 
2.4 Osteoclastogenesis inhibition 
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All the compounds were tested for their ability to inhibit osteoclastogenesis on RAW 246.7 cells, a 
murine monocyte/macrophage cell line with pre-osteoclastic attributes (TIB-71) at 10 M concentration, 
according to the protocol reported in the Experimental Section; the results are collected in Figure 2. All 
the compounds were able to significantly decrease the number of developed osteoclasts compared to the 
controls, in a manner not significantly different from ibandronate. Furoxan and related furazan derivatives 
behave likewise, but a trend of higher activity of the latter compared to the former can be observed. Since 
the congener furazan derivatives, which are devoid of the capacity to release NO, are endowed with anti-
resorptive activity near that of the related furoxans, we have to conclude that in the latter NO does not 
play crucial roles in their antiosteoclastogenic action, unlike what happens in a series of nitrooxy-
substituted BPs we recently developed.
11
 The most active pairs of products, namely 20, 20a, 12, 12a, 25, 
25a, were also tested at 10 M concentration on PBMC cells collected from healthy controls (Figure 3). 
The results are similar to those obtained working with RAW 246.7 cells. The most relevant differences 
are a slightly higher activity of derivatives 12 and 20a. 
2.5 Enzymatic assays and molecular modelling 
One of the main pharmacological targets of BPs is known to be farnesyl pyrophosphate synthase (FPPS);
4
 
therefore, the most active compounds of the series (12, 12a, 20, 20a) were tested for their ability to inhibit 
FPPS and other enzymes of the pre-squalene section of sterol biosynthesis, e.g. squalene synthase (SQS). 
A preliminary test carried out by incubating a rat liver S10 supernatant with labelled (R,S)-[2-
14
C]-
mevalonic acid showed that in the presence of the oxidosqualene cyclase inhibitor U14266A and in the 
absence of bisphosphonate most radioactivity accumulated into a band co-eluting with squalene. In the 
presence of bisphosphonates 12, 20, 20a (10 M) or ibandronate 5 (1 M) the peak of radioactivity co-
eluting with squalene completely disappeared, indicating a possible inhibition of one or more enzymes of 
the pre-squalenic sterol biosynthetic pathway. When tests were repeated with the S100 supernatant, a 
subcellular fraction deprived of most squalene synthase activity, radioactivity mainly accumulated into a 
chromatographic fraction corresponding to unresolved metabolites derived from the hydrolysis of prenyl 
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pyrophosphates. This radioactive fraction diminished by 50% in assays with 1 M ibandronate, while a 
similar effect was not observed with bisphosphonates 12, 12a, 20, 20a. The decrease of radioactivity in 
the prenyl intermediates fraction in the presence of ibandronate was in agreement with inhibition of FPPS, 
a known target of this molecule. The bisphosphonates 12, 12a, 20, 20a, causing an inhibition of the pre-
squalenic biosynthetic pathway following the incubation of (R,S)-[2-
14
C]-mevalonic acid in the S10, but 
not in the S100 cellular fraction, are more likely inhibitors of squalene synthase. The inhibition of 
squalene synthase by compounds 12, 12a, 20, 20a and ibandronate was tested by incubating microsomes 
with the labelled substrate farnesyl pyrophosphate. The values of IC50 are listed in Table 2. Compounds 
20 and 20a are the most active compounds against squalene synthase, showing IC50s of 3.71 ± 0.42 M 
and 7.95 ± 2.23 M respectively. Compounds 12 and 12a have a lower activity, with IC50 ramping around 
20 M. All bisphosphonates tested are less active than ibandronate (IC50 = 0.64 ± 0.16 M), but, from the 
results obtained with the S100 supernatant, appear to be more specific inhibitors of squalene synthase. On 
the basis of these assays, it is not possible to rule out a contribution by GGPPS blockade to the 
antiosteoclastogenic action exerted by compounds 12, 12a, 20, 20a, since an eventual inhibitory effect on 
this enzyme would not result in a significant reduction of squalene or isoprenoid metabolites. 
In the attempt to rationalise the activity profile of the most active compounds 20, 20a compared to 
ibandronate, a molecular modelling investigation was carried out. Taking advantage of the existence of 
crystal structures of human FPPS,
24
 SQS
25
 and GGPPS,
26
 flexible docking of the aforementioned 
bisphosphonates was accomplished in the active site of these three enzymes. In the case of FPPS, since a 
co-crystal with ibandronate has been obtained,
24
 we had the opportunity to validate our approach, 
verifying that AutoDock 4.0 is able to reproduce the crystal pose of the reference inhibitor within the 
limits of experimental error (RMS deviation on heavy atoms 0.52 Å). Additionally, the pose that 
reproduces the experimental binding mode also belongs to the most populated cluster, characterized by 
the best docking score (average Gbinding = -11.34 kcal mol
-1
). Analysing the results for the newly 
synthesised bisphosphonates 20 and 20a the situation is radically different (Figure 4a). Respectively, only 
7 and 3 poses over 200 are located in the enzyme cavity, with average Gbinding = -4.48 and -3.22 
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kcal mol
-1
, while in the remaining runs the inhibitor was placed in the bulk water outside the enzyme. 
This outcome is amenable to the steric bulk of the oxadiazole ring, which hinders these compounds from 
entering the active site. The presence of the heterocycle at one end of the lipophilic tail also appears to 
restrict the conformational freedom of the bisphosphonate head, which is not able to establish interactions 
as effectively as ibandronate does. In particular, each of the phosphonate moieties of ibandronate gives 
rise to electrostatic interactions with the metal ions present in the active site, in addition to charge-
enhanced hydrogen bonds with Arg112, Lys200 and Lys257.
24
 Instead, in the case of compounds 20 and 
20a the bisphosphonate head is rotated, which results in only one of the phosphonate moieties coming 
into close contact with metal ions and Lys200, while Arg112 and Lys257 are not within hydrogen-
bonding distance. The loss of these interactions sums up to the lack of a protonated nitrogen atom capable 
of hydrogen bonding with the side chain of Thr201.
24
 Finally, the phenylsulfonyl substituent on the 
oxadiazole ring protrudes out of the cavity, as evidenced by the representation of the solvent-excluded 
surface of the cavity in Figure 4a; the exposure to water of such a hydrophobic moiety further penalizes 
the binding of these inhibitors. Overall, this picture yields a reasonable interpretation of the lack of 
affinity for FPPS displayed by compounds 20, 20a. The docking results on SQS and GGPPS appear 
markedly different from the ones on FPPS. While these enzymes share some degree of structural 
homology, the solvent accessible volume of the FPPS cavity is only about 260 Å
3
, compared to 608 Å
3
 
for GGPPS and 1240 Å
3
 for SQS. These differences are due to the fact that FPPS is designed to catalyse 
the condensation between dimethyl allyl pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP), 
which are both small substrates. On the contrary, GGPPS needs to accommodate FPP and IPP, while the 
SQS cavity is even broader to allow the condensation of two FPP molecules. Consequently, both 
ibandronate and the oxadiazole bisphosphonates are well accommodated in the cavities of SQS and 
GGPPS. On SQS both ibandronate and newly synthesised BPs display fair docking scores (ibandronate: 
average Gbinding = -7.07 kcal mol
-1
; 20 and 20a: -8.26 and -8.21 kcal mol
-1
, respectively; Figure 4b). The 
phosphonate heads bind similarly, establishing electrostatic interactions with three arginine residues 
(Arg52, Arg77 and Arg218), while the lipophilic tails lie in a pocket lined by mostly hydrophobic 
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residues (Phe72, Tyr73, Leu76, Val179, Leu183, Leu211 and Phe288; Figure 4b). Coming to GGPPS, the 
ligands’ phosphate groups interact with both metal ions present in the active site, as well as with 
positively charged Arg73, Lys151, Lys202, Lys212. While ibandronate establishes a charge-enhanced 
hydrogen bond between its protonated nitrogen and the carboxylate group of Asp188, compounds 20 and 
20a stack their phenylsulfonyl substituent beween the aromatic side chains of His57, Phe156 and Phe184. 
All ligands display similar, good in silico affinity (ibandronate: average Gbinding = -11.15 kcal mol
-1
; 20 
and 20a: -10.84 and -11.55 kcal mol
-1
, respectively; Figure 4c). These figures indicate that there is a 
possibility that binding at GGPPS may contribute to the antiosteoclastogenic effect displayed by 20 and 
20a. 
2.6 Vasodilator activity 
The NO-BPs 12a, 13a, 19a, 20a, 24a, 25a and ibandronate 5 were tested for their ability to relax rat aorta 
strips precontracted with phenylephrine, in view of their potential NO-dependent vasodilator properties. 
All furoxan derivatives were capable of dilating the contracted tissue in a concentration-dependent 
manner, while ibandronate resulted completely inactive. An example of this behaviour is reported in 
Figure 5. The vasodilator potencies (EC50) of the products are collected in Table 3. When the experiments 
were repeated in the presence of 1 M ODQ (1H- 1,2,4 oxadiazolo 4,3-a quinoxalin-1-one), a strong 
decrease in potency was observed, in keeping with a NO-mediated, sGC-dependent vasodilator 
mechanism. The potencies of these hybrids parallel the ones of the simple reference furoxan models,
27
 
while being consistently lower. This is most likely due to the highly hydrophilic character of NO-BPs, 
which reduces their capacity to enter into vascular smooth muscle cells where they are metabolised to NO. 
3. Conclusion 
A new series of bisphosphonates bearing either the nitrogen-containing NO-donor furoxan (1,2,5-
oxadiazole 2-oxide) or the related furazan (1,2,5-oxadiazole) systems in the lateral chain has been 
developed. Their pKa profile is in keeping with that of similar compounds. As expected, 1-hydroxy 
 11 
substituted products show a higher affinity for HAP than their methylene analogues. All the new BPs are 
able to inhibit osteoclastogenesis on RAW 246.7 and PBMC cells at 10 M concentration. The most 
active compounds were tested for their ability to inhibit the mevalonate pathway. The assay indicates that 
they are more potent inhibitors of SQS compared to FPPS, while an involvement of other targets (e.g., 
GGPPS) cannot be ruled out. This finding is in keeping with the results of a molecular modelling 
investigation, but additional experimental work is necessary to draw definitive conclusions on the 
mechanism of action. NO-BPs are able to relax contracted vascular tissue in a concentration-dependent 
manner. A decrease in potency was observed in the presence of ODQ, proving the involvement of NO in 
the vasodilator mechanism. This new series of NO-BPs is worthy of additional studies as potential drugs 
in view of the emerging relationship between osteoporosis and CD. 
4. Experimental Section 
4.1 Chemistry 
1
H and 
13
C-NMR spectra were recorded on a Bruker AC-200 and on a Bruker Avance 300; abbreviations: 
s, singlet; d, doublet; t, triplet; tt, triplet of triplets; m, multiplet; br, broad; Fx, furoxan; Fz, furazan. Low 
resolution mass spectra were recorded with a Finnigan-Mat TSQ-700. Melting points were determined 
with a capillary apparatus (Büchi 540). Flash column chromatography was performed on silica gel 
(Merck Kieselgel 60, 230-400 mesh ASTM); PE stands for 40-60 petroleum ether. The progress of the 
reactions was followed by thin layer chromatography (TLC) on 5 × 20 cm plates with a layer thickness of 
0.25 mm. Anhydrous magnesium sulfate was used as the drying agent for the organic phases. Organic 
solvents were removed under vacuum at 30 °C. Preparative HPLC was performed on a Lichrospher
®
 C18 
column (250 × 25 mm, 10 m) (Merck Darmstadt, Germany) with a Varian ProStar mod-210 with Varian 
UV detector mod-325. When necessary they were developed with iodine, KMnO4 and ammonium 
thiocyanate-iron(III) chloride reagent.
28
 Elemental analyses (C, H, N) were performed by REDOX 
(Monza) and the results are within 0.4% of the theoretical values. Compounds 7,
29
 7a,
29
 8,
30
 8a,
31
 9,
21
 
 12 
14,
29
 14a,
29
 21,
32
 21a,
33
 22,
32
 22a,
34
 23
33
 were synthesised according to literature. Tetrahydrofuran (THF) 
was distilled immediately before use from Na and benzophenone under a positive atmosphere of N2. 
4.1.1 General procedure for the preparation of esters 10, 10a, 11, 11a 
A solution of potassium tert-butylate (0.416 M; 11 mL; 4.58 mmol) in dry THF was added over 90 min to 
a solution of 9 (1.50 g; 4.16 mmol) and the appropriate furazan (7, 8) or furoxan (7a, 8a) (4.58 mmol) in 
dry THF (15 mL), stirred under inert atmosphere between -45 and -15 °C. The mixture was allowed to 
reach room temperature, then diluted with saturated NH4Cl (20 mL) and extracted with Et2O (25 mL). 
The organic phases were collected, washed with saturated NH4Cl (10 mL), dried and concentrated under 
reduced pressure. The crude product was purified by flash chromatography using the appropriate eluent 
obtaining the desired compound as pale yellow oil. 
4.1.1.1 Tetraethyl (5-(4-phenylfurazan-3-yloxy)pentylidene) bisphosphonate (10). Eluent from 
CH2Cl2 to CH2Cl2/MeOH 98/2 v/v; pale yellow oil; 86% yield. 
1
H NMR (200 MHz, CDCl3, TMS): 
 = 1.27-1.37 (m, 12H, -PO(OCH2CH3)2), 1.72-2.17 (m, 6H, -CH2CH2CH2CH-), 2.29 (tt, 1H,
 3
JHH = 5.8 
Hz, 
2
JPH = 24.0 Hz, -CH2CH[PO(OCH2CH3)2]2), 4.07-4.23 (m, 8H, -PO(OCH2CH3)2), 4.46 (t, 2H,
 
3
JHH = 6.6 Hz, -OCH2-), 7.44-8.00 ppm (m, 5H, C6H5); 
13
C NMR (50 MHz, CDCl3, TMS):  = 16.2 (d), 
25.2 (t), 28.5, 36.6 (t, 
1
JPC = 133 Hz), 62.4 (m), 72.3, 125.1, 127.2, 128.8, 130.4, 145.0, 163.4 ppm. MS 
m/z 505 (M+H)
+
. Anal. calcd for C21H34N2O8P2 · 0.5H2O: C 49.12%, H 6.87%, N 5.46%, found: C 
48.92%, H 6.99%, N 5.34%. 
4.1.1.2 Tetraethyl (5-(3-phenylfuroxan-4-yloxy)pentylidene) bisphosphonate (10a). Eluent: from 
CH2Cl2 to CH2Cl2/MeOH 98/2 v/v; pale yellow oil; 60% yield. 
1
H NMR (200 MHz, CDCl3, TMS): 
 = 1.27-1.36 (m, 12H, -PO(OCH2CH3)2), 1.81-2.02 (m, 6H, -CH2CH2CH2CH-), 2.31 (tt, 1H,
 3
JHH = 5.8 
Hz, 
2
JPH = 23.8 Hz, -CH2CH[PO(OCH2CH3)2]2), 4.52 (t, 2H, 
3
JHH = 6.1 Hz, -OCH2-), 4.09-4.25 (m, 
8H, -PO(OCH2CH3)2), 7.46-8.16 ppm (m, 5H, C6H5); 
13
C NMR (50 MHz, CDCl3, TMS):  = 16.2 (d), 
25.2 (t), 28.3, 36.6 (t, 
1
JPC = 133 Hz), 62.4 (t), 70.3, 107.4, 122.4, 126.0, 128.7, 130.3, 162.2 ppm. MS m/z 
 13 
521 (M+H)
+
. Anal. calcd for C21H34N2O9P2: C 48.46%, H 6.58%, N 5.38%, found: C 48.53%, H 6.73%, 
N 5.27%. 
4.1.1.3 Tetraethyl (5-(4-phenylsulfonylfurazan-3-yloxy)pentylidene) bisphosphonate (11). Eluent: 
CH2Cl2/MeOH 98/2 v/v; pale yellow oil; 58% yield. 
1
H NMR (200 MHz, CDCl3, TMS):  = 1.31-1.38 (m, 
12H, -PO(OCH2CH3)2), 1.67-2.13 (m, 6H, -CH2CH2CH2CH-), 2.28 (tt, 1H,
 3
JHH = 5.8 Hz, 
2
JPH = 24.0 
Hz, -CH2CH[PO(OCH2CH3)2]2), 4.11-4.27 (m, 8H, -PO(OCH2CH3)2), 4.37 (t, 2H,
 3
JHH = 6.2 
Hz, -OCH2-), 7.60-8.12 ppm (m, 5H, C6H5); 
13
C NMR (50 MHz, CDCl3, TMS):  = 16.3 (d), 25.0 (t), 
28.2, 36.5 (t, 
1
JPC = 143 Hz), 62.4 (t), 73.3, 128.8, 129.5, 135.3, 137.7, 148.0, 161.1 ppm. MS m/z 569 
(M+H)
+
. Anal. calcd for C21H34N2O10P2S: C 44.37%, H 6.03%, N 4.93%, found: C 44.47%, H 6.11%, N 
4.87%. 
4.1.1.4 Tetraethyl (5-(3-phenylsulfonylfuroxan-4-yloxy)pentylidene) bisphosphonate (11a). Eluent: 
CH2Cl2/MeOH 98/2 v/v; pale yellow oil; 59% yield. 
1
H NMR (200 MHz, CDCl3, TMS):  = 1.35-1.45 (m, 
12H, -PO(OCH2CH3)2), 1.80-2.00 (m, 6H, -CH2CH2CH2CH-), 2.30 (tt, 1H,
 3
JHH = 5.8 Hz, 
2
JPH = 24.0 
Hz, -CH2CH[PO(OCH2CH3)2]2), 4.12-4.28 (m, 8H, -PO(OCH2CH3)2), 4.43 (t, 2H, 
3
JHH = 6.0 
Hz, -OCH2-), 7.60-8.09 ppm (m, 5H, C6H5);
 13
C NMR (50 MHz, CDCl3, TMS):  = 16.3 (d), 25.0 (t), 
26.1, 36.5 (t, 
1
JPC = 132 Hz), 62.4 (t), 71.0, 110.3, 137.9, 128.4, 129.5, 135.4, 158.8 ppm. MS m/z 585 
(M+H)
+
. Anal. calcd for C21H34N2O11P2S: C 43.15%, H 5.86%, N 4.79%, found: C 43.36%, H 6.03%, N 
4.68%. 
4.1.2 General procedure for the preparation of acids 12, 12a, 13, 13a 
Bromotrimethylsilane (2.30 mL; 17.6 mmol; 10 eq) was added over 15 min to a solution of the 
appropriate ester (10, 10a, 11, 11a) (1.76 mmol) in dry CH2Cl2 (10 mL) under inert atmosphere. The 
mixture was stirred at room temperature for 3.5 h, then ice cooled and slowly diluted with MeOH (15 
mL). The resulting mixture was stirred at room temperature for 30 min, then concentrated under reduced 
pressure. After dissolving the crude product in MeOH (15 mL), the resulting solution was concentrated 
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under reduced pressure three times. The crude product was then dissolved in CH3CN (2 mL); the resulting 
solution was diluted with water (8 mL) and the mixture was purified by flash RP-18 chromatography 
(eluent CH3CN/H2O 2/8 v/v) obtaining a foamy solid. The desired compound was obtained as a white 
solid triturating with dry Et2O. 
4.1.2.1 5-(4-Phenylfurazan-3-yloxy)pentylidenebis(phosphonic)acid (12). White solid; 82% yield. 
1
H 
NMR (200 MHz, DMSO-d6, TMS):  = 1.60-2.20 (m, 7H, -CH2CH2CH2CH-), 4.42-4.44 (m, 
2H, -OCH2-), 7.58-7.98 (m, 5H, C6H5), 8.57 ppm (br s, 4H, mobile protons); 
13
C NMR (50 MHz, DMSO-
d6, TMS; a signal is missing, being covered by the solvent):  = 24.9, 28.2, 72.8, 124.5, 127.4, 129.5, 
131.1, 145.3, 163.4 ppm; 
31
P NMR (120 MHz, D2O, H3PO4):  = 23.4 ppm. Anal. calcd for 
C13H18N2O8P2 · 0.15H2O: C 39.53%, H 4.67%, N 7.09%, found: C 39.17%, H 4.7%, N 7.03%. 
4.1.2.2 5-(3-Phenylfuroxan-4-yloxy)pentylidenebis(phosphonic)acid (12a). White solid; 67% yield. 
1
H 
NMR (200 MHz, DMSO-d6, TMS):  = 1.60-2.20 (m, 7H, CH2CH2CH2CH-), 4.48 (m, 2H, -OCH2-), 
7.56-8.08 (m, 5H, C6H5), 9.48 ppm (br s, 4H, mobile protons); 
13
C NMR (50 MHz, DMSO-d6, TMS; a 
signal is missing, being covered by the solvent):  = 24.9, 28.0, 71.7, 107.6, 122.1, 123.3, 129.2, 130.7, 
162.4 ppm; 
31
P NMR (120 MHz, D2O, H3PO4):  = 23.8 ppm. Anal. calcd for C13H18N2O9P2: C 38.25%, 
H 4.44%, N 6.86%, found: C 38.28%, H 4.48%, N 6.85%. 
4.1.2.3 5-(4-Phenylsulfonylfurazan-3-yloxy)pentylidenebis(phosphonic) acid (13). White solid, 55% 
yield. 
1
H NMR (200 MHz, DMSO-d6, TMS):  = 1.40-2.10 (m, 7H, -CH2CH2CH2CH-), 4.33-4.36 (m, 
2H, -OCH2-), 7.76-8.12 (m, 5H, C6H5), 9.88 ppm (br s, 4H, mobile protons);
 13
C NMR (50 MHz, DMSO-
d6, TMS, a signal is missing, being covered by the solvent):  = 24.0, 28.8, 74.0, 128.8, 130.3, 136.3, 
136.8, 148.8, 161.0 ppm; 
31
P NMR (120 MHz, D2O, H3PO4):  = 22.7 ppm. Anal. calcd for 
C13H18N2O10P2S: C 34.22%, H 3.98%, N 6.14%, found: C 34.17%, H 3.98%, N 6.11%. 
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4.1.2.4 5-(3-Phenylsulfonylfuroxan-4-yloxy)pentylidenebis(phosphonic) acid (13a). White solid; 77% 
yield. 
1
H NMR (200 MHz, DMSO-d6, TMS):  = 1.50-2.20 (m, 7H, -CH2CH2CH2CH-), 4.38 (m, 
2H, -OCH2-), 7.74-8.06 (m, 5H, C6H5), 8.31 ppm (br s, 4H, mobile protons); 
13
C NMR (50 MHz, DMSO-
d6, TMS, a signal is missing, being covered by the solvent):  = 24.7, 27.9, 71.3, 110.6, 128.5, 130.2, 
136.2, 137.2, 158.9 ppm; 
31
P NMR (120 MHz, D2O, H3PO4):  = 23.4 ppm. Anal. calcd for 
C13H18N2O11P2S: C 33.06%, H 3.84%, N 5.93%, found: C 32.79%, H 4.01%, N 5.80%. 
4.1.3 General procedure for the preparation of alcohols 15, 15a, 16, 16a 
NaOH (50% w/w; 1.5 eq) was added over a period of 30 min to a stirred solution of the appropriate 
phenylsulfonyl derivative (8, 8a, 14, 14a) (8.0 g) and 1,5-pentanediol (10 eq) in distilled THF (100 mL). 
Acetic acid was added to the mixture that was concentrated under reduced pressure. The residue was 
dissolved in EtOAc (100 mL) and washed twice with H2O (100 mL). The organic layer was dried and 
concentrated under reduced pressure. The crude product was purified by flash chromatography to give the 
pure product as a white solid. 
4.1.3.1 5-(4-Phenylfurazan-3-yloxy)pentan-1-ol (15). Eluent: PE/EtOAc from 80/20 to 60/40 v/v, white 
solid, 86% yield; mp 59-60 °C (iPr2O). 
1
H NMR (300 MHz, CDCl3, TMS):  = 1.34 (s, 1H, OH), 1.50-
1.70 (m, 4H), 1.88-1.97 (m, 2H)(-OCH2CH2CH2CH2CH2OH), 3.66 (t, 2H, 
3
JHH = 6.0 Hz, -CH2OH), 4.44 
(t, 2H, 
3
JHH = 6.6 Hz, -FzOCH2-), 7.44-7.48 (m, 3H, C6H5), 7.93-7.97 ppm (m, 2H, C6H5); 
13
C NMR (75 
MHz, CDCl3, TMS):  = 22.1, 28.6, 32.2, 62.6, 72.8, 125.3, 127.4, 129.0, 130.6, 145.2, 163.6 ppm. MS 
m/z 249 (M+H)
+
. Anal. calcd for C13H16N2O3: C 62.89%, H 6.50%, N 11.28%, found: C 62.50%, H 
6.47%, N 11.19%. 
4.1.3.2 5-(3-Phenylfuroxan-4-yloxy)pentan-1-ol (15a). Eluent: PE/EtOAc 80/20 v/v, white solid, 98% 
yield; mp 91-92 °C (iPr2O). 
1
H NMR (300 MHz, CDCl3, TMS):  = 1.31 (s, 1H; -OH), 1.54-1.73 (m, 4H), 
1.93-2.02 (m, 2H)(-OCH2CH2CH2CH2CH2OH), 3.70 (t, 2H,
3
JHH = 6.0 Hz, -CH2OH), 4.52 (t, 
2H,
3
JHH = 6.6 Hz, -FxOCH2-), 7.44-7.54 (m, 3H, C6H5), 8.12-8.15 ppm (m, 2H, C6H5); 
13
C NMR (75 
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MHz, CDCl3, TMS):  = 22.2, 28.5, 32.1, 62.6, 70.8, 107.6, 122.5, 126.2, 128.9, 130.4, 162.4 ppm. MS 
m/z 265 (M+H)
+
. Anal. calcd for C13H16N2O4: C 59.08%, H 6.10%, N 10.60%, found: C 58.98%, H 
6.07%, N 10.57%. 
4.1.3.3 5-(4-Phenylsulfonylfurazan-3-yloxy)pentan-1-ol (16). Eluent: PE/EtOAc 60/40 v/v, colourless 
oil, 57% yield. 
1
H NMR (300 MHz, CDCl3, TMS):  = 1.39-1.61 (m, 5H), 1.76-1.85 (m, 
2H)(-OCH2CH2CH2CH2CH2OH), 3.61 (t, 2H, 
3
JHH = 6.2 Hz, -CH2OH), 4.31 (t, 2H, 
3
JHH = 6.4 
Hz, -FzOCH2-), 7.54-7.59 (t, 2H, C6H5), 7.67-7.72 (t, 1H, C6H5), 8.00-8.03 ppm (d, 2H, C6H5); 
13
C NMR 
(75 MHz, CDCl3, TMS):  = 21.7, 28.0, 31.8, 62.2, 73.6, 128.7, 129.4, 135.2, 137.5, 148.6, 161.1 ppm. 
MS m/z 313 (M+H)
+
. Anal. calcd for C13H16N2O5S: C 49.99%, H 5.16%, N 8.97%, found: C 49.72%, H 
5.25%, N 9.00%. 
4.1.3.4 5-(3-Phenylsulfonylfuroxan-4-yloxy)pentan-1-ol (16a). Eluent: PE/EtOAc 50/50 v/v, white 
solid, 59% yield; mp 72 °C (iPr2O). 
1
H NMR (200 MHz, CDCl3):  = 1.42 (br s, 1H, -OH), 1.49-2.00 (m, 
6H, -OCH2CH2CH2CH2CH2OH), 3.69-3.74 (m, 2H, -CH2OH), 4.45 (t, 2H, 
3
JHH = 6.3 Hz, -FxOCH2-), 
7.60-7.81 (m, 3H, C6H5), 8.07 ppm (d, 2H, C6H5); 
13
C NMR (50 MHz, CDCl3):  = 21.7, 27.9, 31.8, 62.3, 
71.2, 110.2, 128.3, 129.4, 135.4, 137.8, 158.8 ppm. MS m/z 329 (M+H)
+
. Anal. calcd for 
C13H16N2O6S · 0.25H2O: C 46.91%, H 5.00%, N 8.42%, found: C 47.03%, H 4.80%, N 8.41%. 
4.1.4 General procedure for the preparation of carboxylic acids 17, 17a, 18, 18a 
A solution of Jones reagent (2.5 M, 2.5 eq) was added to a stirred solution of the appropriate alcohol (15, 
15a, 16, 16a) (5.0 g) in acetone (100 mL), cooled at 0 °C. The mixture was allowed to reach room 
temperature and then stirred for 18 h. iPrOH (20 mL) was added, then the mixture was concentrated under 
reduced pressure. The residue was dissolved in Et2O (100 mL), washed with H2O (3 × 100 mL) and then 
extracted with a saturated solution of NaHCO3 (4 × 30 mL). The aqueous layers were acidified with 6 M 
HCl and extracted with Et2O (3 × 100 mL). The combined organic layers were dried, filtered and 
concentrated under reduced pressure to give the pure compound as a white solid. 
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4.1.4.1 5-(4-Phenylfurazan-3-yloxy)pentanoic acid (17). 72% yield; mp 85.5-87.5 °C (iPr2O). 
1
H NMR 
(300 MHz, CDCl3, TMS):  = 1.86-2.00 (m, 4H, -OCH2CH2CH2CH2COOH), 2.49 (t, 2H, 
3
JHH = 7.2 
Hz, -OCH2CH2CH2CH2COOH), 4.48 (t, 2H, 
3
JHH = 6.0 Hz, -FzOCH2-), 7.47-7.50 (m, 3H, C6H5), 7.97-
8.00 (m, 2H, C6H5), 11.55 ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, CDCl3, TMS):  = 21.0, 28.2, 
33.4, 72.2, 125.2, 127.4, 129.0, 130.7, 145.2, 163.6, 179.3 ppm. MS m/z 263 (M+H)
+
. Anal. calcd for 
C13H14N2O4: C 59.54%, H 5.38%, N 10.68%, found: C 59.31%, H 5.37%, N10.58%. 
4.1.4.2 5-(3-Phenylfuroxan-4-yloxy)pentanoic acid (17a). 76% yield; mp 113.5-114.5 °C (iPr2O). 
1
H 
NMR (300 MHz, CDCl3, TMS):  = 1.84-2.05 (m, 4H, -OCH2CH2CH2CH2COOH), 2.49 (t, 2H, 
3
JHH = 7.2 Hz, -OCH2CH2CH2CH2COOH), 4.52 (t, 2H, 
3
JHH = 6.3 Hz, -FxOCH2-), 7.44-7.54 (m, 3H, 
C6H5), 8.10-8.17 (m, 2H, C6H5), 11.48 ppm (br s, 1H, COOH); 
13
C NMR (75 MHz, CDCl3, TMS): 
 = 21.0, 28.0, 33.3, 70.3, 107.6, 122.4, 126.2, 128.9, 130.5, 162.3, 179.2 ppm. MS m/z 279 (M+H)
+
. 
Anal. calcd for C13H14N2O5: C 56.11%, H 5.07%, N 10.07%, found: C 56.10%, H 5.11%, N 10.03%. 
4.1.4.3 5-(4-Phenylsulfonylfurazan-3-yloxy)pentanoic acid (18). 65% yield; mp 96-97 °C (iPr2O).
 1
H 
NMR (200 MHz, CDCl3):  = 1.74-2.00 (m, 4H, -OCH2CH2CH2CH2COOH), 2.47 (t, 2H, 
3
JHH = 7.1 
Hz, -OCH2CH2CH2CH2COOH), 4.41 (t, 2H, 
3
JHH = 5.8 Hz, -FzOCH2-), 7.60-7.81 (m, 3H, C6H5), 8.11 
ppm (d, 2H, C6H5); 
13
C NMR (50 MHz, CDCl3):  = 20.7, 27.7, 33.1, 73.2, 128.6, 129.5, 135.3, 137.6, 
146.6, 161.1, 177.0 ppm. MS m/z 327 (M+H)
+
. Anal. calcd for C13H14N2O6S: C 47.85%, H 4.32%, N 
8.58%, found: C 47.63%, H 4.29%, N 8.50%. 
4.1.4.4 5-(3-Phenylsulfonylfuroxan-4-yloxy)pentanoic acid (18a). 70% yield; mp 117-120 °C (iPr2O).
 
1
H NMR (200 MHz, CDCl3):  = 1.79-2.04 (m, 4H, -OCH2CH2CH2CH2COOH), 2.50 (t, 2H, 
3
JHH = 7.1 
Hz, -OCH2CH2CH2CH2COOH), 4.45 (t, 2H, 
3
JHH = 5.8 Hz, -FxOCH2-), 7.58-7.81 (m, 3H, C6H5), 8.06 
ppm (d, 2H, C6H5);
 13
C NMR (50 MHz, CDCl3):  = 20.6, 27.5, 33.1, 70.7, 110.2, 128.3, 129.5, 135.4, 
137.8, 158.7, 179.2 ppm. MS m/z 343 (M+H)
+
. Anal. calcd for C13H14N2O7S: C 45.61%, H 4.12%, N 
8.18%, found: C 45.96%, H 4.14%, N 8.13%. 
 18 
4.1.5 General procedure for the preparation of bisphosphonic acids 19, 19a, 20, 20a 
A solution of the appropriate carboxylic acid (17, 17a, 18, 18a) (1.0 g) in thionyl chloride (10 mL, fresh 
distilled) was stirred at room temperature for 3 h under N2. Thionyl chloride was then distilled under 
reduced pressure, and the system was refilled with N2. Thereafter, dry THF (10 mL) was added to the 
residue and then distilled under reduced pressure three times. The residue was dissolved in dry THF (10 
mL) and to the resulting solution, stirred under N2 at 0 °C, was added trimethylphosphite (1 eq). The 
mixture was then allowed to reach room temperature and stirred for 18 h. The reaction mixture containing 
the acylphosphonate (B) was slowly added to a stirred solution of dimethylphosphite (2 eq) and 
diethylamine (0.4 eq) in dry THF (20 mL) under N2 and kept at 0 °C. The mixture was stirred at 0 °C for 
3 h, allowed to reach room temperature, and then poured into 0.5 M HCl (20 mL) and Et2O (30 mL). The 
ethereal fraction was extracted with 0.5 M HCl (25  20 mL). The collected aqueous layers were 
extracted with CH2Cl2 (10  50 mL). The organic layers were dried and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (CH2Cl2/MeOH 98/2 v/v to 9/1 v/v) to 
yield the unstable tetramethylester (C) as pale yellow oil. The compounds were immediately used for the 
next synthetic step. Bromotrimethylsilane (2.5 eq) was slowly added to a solution of the appropriate 
tetramethylester (C) (0.70 g) in dry CH2Cl2 (20 mL), then stirred under inert atmosphere for 48 h. The 
reaction was followed via RP-18 TLC (CH3CN/H2O 5/5 v/v). The solution was cooled at 0 °C, then dry 
MeOH (10 mL) was added and the mixture was allowed to reach room temperature. The solution was 
then concentrated under reduced pressure. The residue was dissolved in dry MeOH (10 mL) and 
concentrated under reduced pressure twice. The crude material was purified by preparative HPLC 
(Lichrospher 250 × 25 C18, MeOH/H2O 3/7 v/v, flow rate 39 mL min
-1
,  224 nm, injection volume 2 
mL) to give the desired product as a white solid. 
4.1.5.1 (5-(4-Phenylfurazan-3-yloxy)-1-hydroxypentylidene)bis(phosphonic)acid (19). 15% yield. 
1
H 
NMR (300 MHz, D2O):  = 1.60 (br s, 4H, -OCH2CH2CH2CH2-), 1.80-2.00 (m, 2H,-OCH2CH2CH2CH2-), 
4.05 (br s, 2H, -FzOCH2-), 7.07-7.15 (m, 3H, C6H5), 7.46-7.48 ppm (m, 2H, C6H5); 
13
C NMR (75 MHz, 
 19 
D2O):  = 19.8 (t, 
2
JPC = 6.0 Hz), 29.0, 33.6, 72.9, 73.6 (t, 
1
JPC = 146 Hz), 124.3, 127.1, 129.0, 130.9, 
145.3, 163.4 ppm; 
31
P NMR (120 MHz, D2O, H3PO4):  = 20.3 ppm. Anal. calcd for C13H18N2O9P2 · 1.5 
H2O: C 35.87%, H 4.86%, N 6.44%, found: C 35.99%, H 4.73%, N 6.44%. 
4.1.5.2 (5-(3-Phenylfuroxan-4-yloxy)-1-hydroxypentylidene)bis(phosphonic)acid (19a) 31% yield. 
1
H 
NMR (300 MHz, D2O):  = 1.78-2.04 (m, 6H, -OCH2CH2CH2CH2-), 4.49 (t, 2H, 
3
JHH = 6.9 
Hz, -FxOCH2-), 7.54-7.56 (m, 3H, C6H5), 7.99-8.00 ppm (m, 2H, C6H5); 
13
C NMR (75 MHz, D2O): 
 = 20.7 (t, 
2
JPC = 5.5 Hz), 29.6, 36.1, 72.2, 76.8 (t, 
1
JPC = 134.0 Hz), 110.3, 121.7, 126.7, 129.2, 131.4, 
163.0 ppm; 
31
P NMR (120 MHz, D2O, H3PO4):  = 20.4 ppm. Anal. calcd for C13H18N2O10P2 · 2.0 H2O: 
C 33.92%, H 4.82%, N 6.09%, found: C 33.93%, H 4.56%, N 6.04%. 
4.1.5.3 (5-(4-Phenylsulfonylfurazan-3-yloxy)-1-hydroxypentylidene)bis(phosphonic)acid (20). 25% 
yield. 
1
H NMR (200 MHz, D2O):  = 1.70-1.88 (m, 4H), 1.98-2.12 (m, 2H, -OCH2CH2CH2CH2-), 4.35 (t, 
2H, 
3
JHH = 6.0 Hz, -FzOCH2-), 7.70 (t, 2H, C6H5), 7.83 (t, 1H, C6H5), 8.06 ppm (d, 2H, C6H5);
 13
C NMR 
(50 MHz, D2O):  = 17.0, 26.0, 30.5, 70.6 (t, 
1
JPC = 143.0 Hz), 71.4, 126.1, 127.4, 133.1, 133.7, 145.7, 
158.6 ppm; 
31
P NMR (80 MHz, D2O, H3PO4):  = 20.3 ppm. Anal. calcd for C13H18N2O11P2S · 0.75 H2O: 
C 32.14%, H 4.04%, N 5.77%, found: C 31.78%, H 4.09%, N 5.66%. 
4.1.5.4 (5-(3-Phenylsulfonylfuroxan-4-yloxy)-1-hydroxypentylidene)bis(phosphonic)acid (20a). 30% 
yield. 
1
H NMR (200 MHz, D2O):  = 1.71-2.05 (m, 6H, -OCH2CH2CH2CH2-), 4.34 (t, 2H, 
3
JHH = 5.6 
Hz, -FxOCH2-), 7.55-7.78 (m, 3H, C6H5), 7.95 ppm (d, 2H, C6H5); 
13
C NMR (50 MHz, D2O):  = 17.2, 
25.9, 30.4, 69.1, 70.7 (t, 
1
JPC = 141.0 Hz), 108.5, 125.8, 127.3, 133.5, 133.8, 156.7 ppm; 
31
P NMR (80 
MHz, D2O, H3PO4):  = 20.2 ppm. Anal. calcd for C13H18N2O12P2S · 2.5 H2O: C 29.28%, H 4.35%, N 
5.25%, found: C 29.18%, H 4.09%, N 5.07%. 
4.1.6 General procedure for the preparation of bisphosphonic acids 24, 24a, 25, 25a 
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The pH of a solution of 23 (0.36 g; 1.38 mmol) in water (4 mL) was adjusted to 12 by slowly adding 2 M 
NaOH, then a solution of the appropriate bromomethyl-derivative (21, 21a, 22, 22a) (0.9 eq) in CH3CN 
(4 mL) was added. The mixture was stirred at room temperature maintaining the pH at 12 by addition of 2 
M NaOH. Subsequently, phenylsulfonyl chloride (1 eq) was added, the mixture was stirred at pH 12 until 
a clear solution was obtained, then pH was adjusted to 8 with 1 M HCl. The mixture was washed with 
CH2Cl2 (3  10 mL), then concentrated under reduced pressure. The residue (10 mL) was percolated 
through Dowex 50W-X8 (200-400 mesh hydrogen form; 20 mL resin bed, 34 meq) eluting with water 
until neutrality of the eluate. The eluate was concentrated under reduced pressure to obtain the desired 
compound as a white solid. 
4.1.6.1 [4-(N-Methyl-N-[(4-methylfurazan-3-yl)methyl]-1-hydroxybutylidene]bis(phosphonic)acid 
(24). 36% yield; mp 138 °C. 
1
H NMR (200 MHz, D2O):  = 1.74-2.14 (m, 
4H, -CH2CH2C(OH)[PO(OH)2]2), 2.30 (s, 3H, FzCH3), 2.87 (s, 3H, -CH2N(CH3)CH2CH2-), 3.09-3.37 (m, 
2H, -CH2N(CH3)CH2CH2-), 4.52 ppm (s, 2H, -CH2N(CH3)CH2CH2-); 
13
C NMR (50 MHz, D2O):  = 4.54, 
16.5 (t, 
2
JPC = 6.3 Hz), 27.5, 37.8, 44.9, 54.4, 70.1 (t, 
1
JPC = 140.0 Hz), 144.6, 148.5 ppm. Anal. calcd for 
C9H19N3O8P2 · 1.1 H20: C 28.52%, H 5.64%, N 11.07%, found: C 28.17%, H 5.40%, N 10.88%. 
4.1.6.2 [4-(N-Methyl-N-[(3-methylfuroxan-4-yl)methyl]-1-hydroxybutylidene]bis(phosphonic)acid 
(24a). 71% yield; mp 214 °C dec. 
1
H NMR (200 MHz, D2O):  = 1.70-2.07 (m, 
4H, -CH2CH2C(OH)[PO(OH)2]2), 2.07 (s, 3H, FxCH3), 2.87 (s, 3H, -CH2N(CH3)CH2CH2-), 3.06-3.41 (m, 
2H, -CH2N(CH3)CH2CH2-), 4.45 ppm (s, 2H, -CH2N(CH3)CH2CH2-); 
13
C NMR (50 MHz, D2O):  = 4.39, 
16.5 (t, 
2
JPC = 6.8), 27.5, 37.9, 46.2, 54.4, 70.2 (t, 
1
JPC = 140.0 Hz), 113.3, 148.0 ppm. Anal. calcd for 
C9H19N3O9P2 · 1.5 H20: C 26.87%, H 5.51%, N 10.45%, found: C 26.54%, H 5.30%, N 10.17%. 
4.1.6.3 
[4-(N-Methyl-N-[(4-carbamoylfurazan-3-yl)methyl]-1-hydroxybutylidene]bis(phosphonic)acid (25). 
34% yield. 
1
H NMR (200 MHz, D2O):  = 1.76-2.18 (m, 4H, -CH2CH2C(OH)[PO(OH)2]2), 2.89 (s, 
 21 
3H, -CH2N(CH3)CH2CH2-), 3.18-3.41 (m, 2H, -CH2N(CH3)CH2CH2-), 4.74-4.87 ppm (m, 
2H, -CH2N(CH3)CH2CH2-); 
13
C-NMR (50 MHz, D2O):  = 16.4 (t, 
2
JPC = 7.3 Hz), 27.4, 38.2, 45.7, 54.9, 
70.2 (t, 
1
JPC = 140 Hz), 144.9, 145.9, 157.3 ppm. Anal. calcd for C9H17NaN4O9P2 · 1.14 H20: C 25.10%, 
H 4.51%, N 13.01%, found: C 25.50%, H 4.65%, N 12.60%. 
4.1.6.4 
[4-(N-Methyl-N-[(3-carbamoylfuroxan-4-yl)methyl]-1-hydroxybutylidene]bis(phosphonic)acid 
(25a). 40% yield. 
1
H NMR (200 MHz, D2O):  = 1.81-2.04 (m, 4H, -CH2CH2C(OH)[PO(OH)2]2), 2.89 (s, 
3H, -CH2N(CH3)CH2CH2-), 3.29 (br t, 2H, -CH2N(CH3)CH2CH2-), 4.70 ppm (covered by the solvent 
peak, 2H, -CH2N(CH3)CH2CH2-); 
13
C NMR (50 MHz, D2O):  = 16.4 (t, 
2
JPC = 6.7 Hz), 27.4, 38.2, 47.7, 
55.1, 70.2 (t, 
1
JPC = 140.0 Hz), 108.5, 147.4, 155.1 ppm. Anal. calcd for C9H18N4O10P2 · 1.5 H20: C 
25.07%, H 4.91%, N 12.99%, found: C 25.27%, H 4.82%, N 12.63%. 
4.1.7 Determination of pKa values 
Potentiometric titrations of compounds were performed with the GlpKa apparatus (Sirius Analytical 
Instruments Ltd., Forest Row, East Sussex, UK). Ionization constants were determined as outlined in 
literature: the aqueous titrations were carried out under N2 at 25.0 ± 0.1 °C, and final data were obtained 
with the Multiset approach.
35
 Ionization constant measurement of compounds 24, 24a, 25, 25a was 
repeated in different methanol-water mixtures (18-40% wt); aqueous pKa values were obtained by 
extrapolation at 0% methanol using the Yasuda-Shedlovsky procedure.
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4.1.8 Adsorption of BPs to HAP 
HAP (150 mg, Aldrich) was equilibrated in 50 mL of 0.05 M Tris-HCl pH 7.4 for 24 h at 37 °C according 
to literature.
17,19
 The BPs (1 mM) were incubated in HAP suspension at 37 °C and magnetically stirred. 
After 0 h, 6 h and 24 h, 1 mL of suspension was centrifuged (10000 rpm, 10 min), and the concentration 
of the BPs in the supernatant was determined by RP-HPLC. The HPLC system consisted of an Agilent 
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1200 chromatograph system equipped with a multiple wavelength detector SL (Agilent) and a ZORBAX 
Eclipse XDB C18 column (150  4 mm, 5 m, Agilent). The mobile phase consisted of methanol/10 mM 
phosphate buffer pH 7.4 containing 1 mM tetrabutylammonium hydrogen sulfate (60/40 v/v for 
compounds 12, 12a, 13, 13a, 19, 19a, 20, 20a; 40/60 v/v for compounds 24, 24a, 25, 25a). The flow-rate 
was 1.2 mL/min, and the injection volume was 20 L (Rheodyne, Cotati, CA). The peaks were monitored 
at 226 nm. 
4.2 Biological methods 
Recombinant human M-CSF was purchased from R&D Systems (Abingdon, UK) and recombinant 
human RANKL was from Alexis (San Diego, CA). Samples from peripheral blood (PB) were obtained 
from healthy controls, showing normal bone metabolism (evaluated by bone densitometry). In order to 
enrol a homogeneous group of healthy controls we adopted the following exclusion criteria: chronic 
diseases; therapies with medications which could increase osteoclastogenesis (steroids, glucocorticoids); 
therapies with calcium, vitamin D, phosphorus. Informed consent was obtained to comply with 
institutional policies. 
4.2.1 Cell cultures 
PBMCs, collected from healthy controls, were isolated after centrifugation over a density gradient 
(Lymphoprep, Nycomed Pharma, Norway) and cultured in a 24-well plate at a density of 2·10
6
 cells mL
-1
 
in -MEM (Invitrogen, UK) supplemented with 10% Fetal Bovin Serum (FBS, BioWhittaker, 
Valkersville, MD), penicillin (100 U mL
-1
) and streptomycin (100 g mL
-1
). To obtain fully differentiated 
human OCs, PBMCs were then cultured with/without M-CSF (25 ng mL
-1
) from day 0 and RANKL (30 
ng mL
-1
) from day 10. Culture supernatants were changed on days 5 and 10, when medium was either 
refreshed and supplemented or not with the agents described above. They were all prepared as stock 
solutions at 10
-3
 M concentration  in distilled water, aliquoted and stored at -20 °C. Cultures were stopped 
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after 15 days, mature OCs were identified as multinucleated cells containing three or more nuclei and 
positive for the expression of TRAP and V 3 (vitronectin receptor). 
4.2.2 Culture of RAW 246.7 cells 
As a model system of osteoclastogenesis we have used a clone of RAW 246.7 murine 
monocyte/macrophagic cell line (TIB-71), purchased from American Type Culture Collection (ATCC, 
Rockville, MD). RAW 246.7 cells were cultured in a 24-well plate at a density of 1∙104 cell mL-1 in 
-MEM (Invitrogen, UK) supplemented with 10% Fetal Bovin Serum (FBS, BioWhittaker, Walkersville, 
MD), penicillin (100 U mL
-1
) and streptomycin (100 g mL
-1
). After 24 h of culture, media were changed 
and replaced by one containing RANKL (30 ng mL
-1
) and tested compounds. At day 3 media were 
removed and cells were washed with PBS and subsequently fixed for 30 min in a solution of 4% 
paraformaldehyde and stained for tartrate-resistant acid phosphatase solution (TRAP, Sigma) according to 
the manufacturer. 
4.2.3 Microsomal enzyme preparation 
Cellular fractions (10,000  g, 100,000  g supernatants and microsomes, respectively) of rat liver were 
prepared as described by Popjak.
36
 All procedures were performed at 4 °C. Briefly, livers were 
homogenized in 2.5 volumes of 0.1 M potassium phosphate buffer, pH 7.4, containing 5 mM MgCl2 and 
30 mM nicotinamide. Homogenates were centrifuged at 10,000 × g for 30 min and the 10,000 × g 
supernatant (S10) was aliquoted and stored at -80 °C. To obtain the microsomes, the S10 was further 
centrifuged at 100,000  g for 60 min. The pelletted microsomes were resuspended in one-tenth volume 
of the original homogenate. Microsomes and 100,000 × g supernatant (S100) were aliquoted and stored 
at -80 °C. Proteins were assayed by the BCA method (Pierce) using bovine serum albumin as a standard. 
4.2.4 Inhibition of the section of sterol biosynthesis ranging from mevalonic acid to squalene in rat 
liver S10 or S100 cellular fractions 
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For the inhibition test, bisphosphonates 12, 12a, 20, 20a were dissolved in methanol and sodium 
ibandronate, tested as a reference inhibitor, was dissolved in 0.1 M sodium phosphate buffer, pH 7.4 
(PBS). Rat liver S10 or S100 were incubated with (R,S)-[2-
14
C]mevalonic acid (0.05 Ci , 55 mCi mmol
-1
, 
2.04 GBq mmol
-1
) (Amersham Pharmacia Biotech, UK), in the presence of 0.2 mM U14266A, an 
oxidosqualene cyclase inhibitor.
37
 The labelled substrate, U14266A, bisphosphonates 12, 12a, 20, 20a 
were added as organic solution to test tubes containing Tween-80 (final concentration 0.2 mg mL
-1
) and 
the solvent was evaporated under a stream of nitrogen. Residues were redissolved in 50 L of PBS, 
containing 5 mM MgCl2, 4 mM MnCl2, 30 mM nicotinamide, 2 mM ATP. 50 L of S10 or S100 (2 mg 
protein) were then added to test tubes. Assay tubes were flushed with N2, capped, and incubated at 30 °C 
for 60 min. The inhibition by sodium ibandronate was tested under the same conditions, except for the 
addition of the inhibitor, which was directly transferred as a PBS solution into the test tubes containing 
the reaction mixture freed from solvent. The enzymatic reaction was stopped by adding 20 L of 5 M 
HCl and the mixture was kept at 37 °C for 30 min to complete the hydrolysis of prenyl pyrophosphate. 
Hydrolysis products were extracted twice with petroleum ether (1.5 and 1 mL). Extracts were spotted on 
TLC plates (Alufolien Kieselgel 60F254, Merck, Darmstadt, Germany) using benzene/acetone (90/10 
v/v) as the developing solvent, and authentic standards of geraniol, farnesol, squalene, oxidosqualene, 
lanosterol and cholesterol as reference compounds. Labelled metabolites were determined by scanning 
TLC plates with a System 200 Imaging Scanner (Hewlett-Packard, Palo Alto, CA, USA). Prenol 
references were detected by iodine vapour. Under our experimental conditions (plugged test tubes with no 
NADPH added, in the presence of an oxidosqualene cyclase inhibitor) only one major radioactive product 
(about 80% of total extract radioactivity) co-chromatographing with squalene was detected in control tests 
(no bisphosphonate inhibitors) incubated with the S10 cellular fraction. 
4.2.5 Inhibition of squalene synthase activity in rat liver microsomes 
The substrate [1-
3
H]-FPP (0.02 Ci, 26.2 Ci mmol
-1
, 969.4 GBq mmol
-1
) (PerkinElmer Life and 
Analytical Science), 0.2 mM U14266A (oxidosqualene cyclase inhibitor) and different concentrations of 
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bisphosphonates, dissolved in methanol, were added to test tubes containing Tween-80 (final 
concentration 0.2 mg mL
-1
). To the mixture freed from solvent and redissolved in 50 L of PBS 
containing 5 mM MgCl2, 30 mM nicotinamide, 20 mM NaF and 2 mM NADPH, 50 L of microsomes (3 
mg protein) were added. Sodium ibandronate, dissolved in PBS, was used as reference inhibitor. Assay 
tubes were flushed with N2, capped, and incubated at 30 °C for 60 min. The enzymatic reaction was 
stopped by adding methanolic KOH (1 mL, 10% w/v) and heating at 80 °C for 30 min in a water bath. 
The reaction mixture was extracted twice with petroleum ether (1.5 and 1 mL) and the synthesized [
3
H]-
squalene was counted in Ready GelTM (Beckman) using a Packard liquid scintillation counter. Control 
incubations were carried out in the same conditions, in the absence of bisphosphonate inhibitors. The 
efficiency of the petroleum ether extraction was about 90%, as indicated by the recovery of [
14
C]-
squalene added at the end of the enzymatic reaction as a tracer. Extracts from both control and inhibition 
tests were analysed by TLC, using cyclohexane/ethyl acetate (85/15, v/v) as a developing solvent and 
authentic standards of cholesterol, lanosterol, oxidosqualene, and squalene as reference compounds. 
Labelled products were determined by scanning with a System 200 Imaging Scanner (Hewlett-Packard, 
Palo Alto, CA, USA). The radiochromatographic analysis showed that, in the control test, 95% of 
radioactivity accumulated into a single peak co-chromatographing with squalene. In order to calculate the 
IC50 values, the results were expressed as % of radioactivity extracted with respect to the control 
incubations in the absence of inhibitors. 
4.2.6 Statistical analyses 
Statistical analyses were performed with Prism 5.0. We compared the results by means of Student’s 
paired t-test. The results were considered statistically significant for p < 0.05. IC50 values (inhibitor 
concentrations that decreased enzymatic conversion by 50%) relative to squalene synthase activity were 
calculated by nonlinear regression analysis of the residual activity versus the log of inhibitor 
concentration using statistical software XLfit 5.1 from IDBS (Guildford, Surrey, UK). 
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4.2.7 Vasodilator activities 
Thoracic aortas were isolated from male Wistar rats weighing 180-200 g. As few animals as possible 
were used. The purposes and the protocols of our studies were approved by the Ministero della Salute, 
Rome, Italy. The endothelium was removed and the vessels were helically cut: three strips were obtained 
from each aorta. The tissues were mounted under 1.0 g tension in organ baths containing 30 mL of Krebs-
bicarbonate buffer with the following composition (mM): NaCl 111.2, KCl 5.0, CaCl2 2.5, MgSO4 1.2, 
KH2PO4 1.0, NaHCO3 12.0, glucose 11.1, maintained at 37 °C and gassed with 95% O2-5% CO2 
(pH = 7.4). The aortic strips were allowed to equilibrate for 120 min and then contracted with 1 M 
L-phenylephrine. When the response to the agonist reached a plateau, cumulative concentrations of the 
vasodilating agent were added. Results are expressed as EC50 ± SE ( M). The effects of 1 M ODQ on 
relaxation were evaluated in separate series of experiments. ODQ was added to the organ bath 5 minutes 
before the contraction. Responses were recorded by an isometric transducer connected to the MacLab 
System PowerLab (ADInstruments Ltd, Oxfordshire, UK). Addition of the drug vehicle (DMSO) had no 
appreciable effect on contraction level. 
4.3 Molecular modelling 
The molecular models of ibandronate, 20 and 20a were constructed using standard bond lengths and 
angles with the MOE software package.
38
 In accordance with their pKa values (Table 1), all compounds 
were modelled with three of the four phosphonate hydroxyl groups in their ionized state; in the case of 
ibandronate the basic nitrogen atom was modelled as protonated. Following truncated Newton-Raphson 
geometry optimization with the MMFF94s force field (MMFF94 charges, GB/SA implicit solvent model) 
until the gradient was lower than 0.001 kcal mol
-1
 Å
-1
, a Monte Carlo conformational search was carried 
out with the StochasticCSearch module implemented in MOE. The most stable conformer was then 
chosen for further optimization by an ab initio HF/6-31G(d) method using the GAMESS-US package;
39
 
on the equilibrium geometry, atom-centred point charges were derived by fitting the quantum-mechanical 
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electrostatic potential with the RESP method.
40
 The experimental X-ray structures of human FPPS in 
complex with ibandronate (PDB ID 2F94), human SQS in complex with CP-320473 (PDB ID 1EZF) and 
human GGPPS in complex with geranylgeranyl diphosphate (PDB ID 2Q80) were retrieved from the 
Protein Data Bank.
41
 While only one monomer is present in the FPPS asymmetric unit, a trimer and an 
hexamer are found for SQS and GGPPS, respectively. Since neither active site involves the interface 
between monomers, only one monomer was considered. Two short loops are missing from the crystal 
structure of SQS and GGPPS (10-aminoacid and 6-aminoacid long, respectively). Since these loops do 
not contribute to defining the shape of the active sites they were not modelled; rather, the C- and N- chain 
terminals at the boundaries of the missing segments were simply capped with a N-methylamide and an 
acetyl group, respectively. After removing co-crystallized inhibitors, missing hydrogen atoms were added 
to the three enzymes in standard positions, then their coordinates were optimized with the SANDER 
module of the AMBER 10 software package,
42
 while heavy atoms were harmonically restrained to the 
initial X-ray crystal positions with a force constant of 1000 kcal mol
-1
 Å
-2
. All molecular mechanics 
optimizations on the proteins were accomplished using parameters and electrostatic charges of the 
AMBER99 force field. The volume of the active sites was computed with the VOIDOO program.
43
 
Docking of the inhibitors was carried out using AutoDock 4.0.1.
44-46
 A grid with a 0.375 Å step size was 
centred on the active site and energy maps were pre-calculated with AutoGrid, then flexible docking was 
carried out with AutoDock. The target proteins were kept rigid, while ligands were left free to explore the 
conformational space inside the enzyme cavities; 200 separate docking simulations were run on each 
target using the Lamarckian genetic algorithm with default parameters. Docking poses were clustered 
according to their RMS deviation from the starting reference structure. 
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Table 1. pKa values and affinity for HAP of ibandronate and of final bisphosphonates 
Compd 
Dissociation constants Affinity to HAP
a
 
pKa1 pKa2 ± SD pKa3 ± SD pKa4 ± SD pKa5 ± SD 0 h 6 h 24 h 
5
b
 - 2.84 6.08 9.80 10.43 71 ± 2 56 ± 1 56 ± 3 
12 < 1.5 2.81 ± 0.02 6.88 ± 0.01 11.4 ± 0.1 - 75 ± 3 54 ± 3 44 ± 1 
12a < 1.5 2.67 ± 0.02 6.86 ± 0.01 11.2 ± 0.1 - 76 ± 1 51 ± 2 44 ± 2 
13 < 1.5 2.69 ± 0.04 7.00 ± 0.03 10.7 ± 0.1 - 64 ± 2 48 ± 4 40 ± 5 
13a < 1.5 2.64 ± 0.03 6.87 ± 0.02 11.6 ± 0.1 - 70 ± 2 57 ± 2 42 ± 3 
19 < 1.5 2.69 ± 0.04 6.66 ± 0.02 11.0 ± 0.2 - 56 ± 1 40 ± 4 33 ± 2 
19a < 1.5 2.90 ± 0.02 6.86 ± 0.01 11.2 ± 0.1 - 59 ± 4 36 ± 3 27 ± 2 
20 < 1.5 2.80 ± 0.05 6.64 ± 0.03 10.6 ± 0.1 - 56 ± 2 41 ± 1 34 ± 1 
20a < 1.5 2.52 ± 0.03 6.65 ± 0.01 11.3 ± 0.1 - 59 ± 2 42 ± 1 33 ± 2 
24 < 1.5 2.05 ± 0.06 6.05 ± 0.01 7.45 ± 0.02 11.1 ± 0.1 69 ± 2 54 ± 1 46 ± 1 
24a < 1.5 2.26 ± 0.07 5.89 ± 0.01 7.13 ± 0.01 11.2 ± 0.1 69 ± 2 51 ± 4 46 ± 2 
25 < 1.5 2.04 ± 0.09 6.02 ± 0.02 7.65 ± 0.03 11.0 ± 0.1 70 ± 2 51 ± 2 52 ± 2 
25a < 1.5 2.16 ± 0.06 6.03 ± 0.01 7.36 ± 0.01 10.8 ± 0.1 62 ± 1 49 ± 2 46 ± 1 
a 
Percentage of residual BP in solution; all values are expressed as mean ± SD, n = 4-6. 
b 
Dissociation constants reported in literature.
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Table 2. Inhibitory effect of compounds 5, 12, 12a, 20, 20a on squalene synthase enzyme in rat liver 
microsomes 
 
Compd IC50 [ M]
a
 
5 0.64 ± 0.16 
12 17.68 ± 1.72 
12a 22.95 ± 3.57 
20 3.71 ± 0.42 
20a 7.95 ± 2.23 
a
 Data expressed as mean ± SE (three different experiments in duplicate). 
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Table 3. Vasodilating activity of compounds 5, 12a, 13a, 19a, 20a, 24a, 25a 
Compounds EC50 [ M]
a
 EC50ODQ [ M]
b
 
5 inactive not tested 
12a 73 ± 18 
c 
13a 0.20 ± 0.03 193 ± 36 
19a 108 ± 20 
c
 
20a 0.23 ± 0.03 192 ± 27 
24a 45 ± 3 
c
 
25a 35 ± 2 
c
 
a
 Data expressed as mean ± SE, n = 3-15. 
b
 Experiments performed in the presence of 1 M ODQ. 
c
 At the maximal concentration tested (1∙10-4 M) vasodilation does not reach 50%. 
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Figure legends 
 
Figure 1. Structures of bisphosphonic acids (1), pyrophosphoric acid (2) and examples of first (etidronate, 
3), second (alendronate, 4; ibandronate, 5) and third generation (zoledronate, 6) bisphosphonates. 
 
Figure 2. TRAP
+
 RAW-OCs number. The number of TRAP
+ 
RAW-OCs containing three or more 
nuclei/cell were quantified from three independent experiments. Data are presented as the mean ± SD; 
statistical differences from controls not treated with N-BPs (10 M): 
*
 p < 0.001; 
**
 p < 0.00001. The 
result of an ANOVA statistical test is 0.0001. 
 
Figure 3 TRAP
+
 MNC number. The number of TRAP
+ 
OCs containing three or more nuclei/cell were 
quantified from nine independent wells per condition. Data are presented as the mean ± SD; statistical 
differences from controls not treated with N-BPs (10 M): 
*
 p < 0.05; 
**
 p < 0.002. The result of an 
ANOVA statistical test is 0.0001. 
 
Figure 4. Ibandronate (thicker lines) and compound 20 (thinner lines) docked in FPPS (a), SQS (b) and 
GGPPS (c), respectively. Polar hydrogens have been omitted for clarity. The solvent-excluded surface of 
the cavity has been included to evidence how bisphosphonates 20 and 20a partially protrude from the 
FPPS cavity, while they are well accommodated in the active sites of SQS and GGPPS. 
 
Figure 5. Concentration-response curves of 20a in the absence and in the presence of 1 M ODQ. 
 
Scheme 1. a) t-BuO
-
K
+
, dry THF, -15 °C for compounds 10, 10a, -45 °C for compounds 11, 11a; b) 
TMSBr, CH2Cl2; c) MeOH, 0 °C to rt. 
 
Scheme 2. a) 1,5-Pentanediol, NaOH 50% w/w, THF; b) Jones reagent, acetone, 0 °C to rt; c) SOCl2; d) 
P(OMe)3, dry THF, 0 °C to rt; e) HPO(OMe)2, Et2NH, dry THF, 0 °C to rt; f) TMSBr, CH2Cl2; g) MeOH, 
0 °C to rt. 
 
Scheme 3. a) 2 M NaOH, pH 12, H2O, CH3CN. 
 35 
 
 
Figure 1. 
 36 
 
 
Figure 2. 
 37 
 
 
Figure 3. 
 38 
 
 
Figure 4. 
 39 
 
 
Figure 5. 
 40 
 
 
Scheme 1. 
 41 
 
 
Scheme 2. 
 42 
 
 
Scheme 3. 
